Oragenics Inc. (OGEN)
0.29
-0.01 (-2.13%)
At close: Jan 15, 2025, 1:33 PM
undefined% (undefined)
| Bid | 0.29 |
| Market Cap | 3.70M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -6.97 |
| PE Ratio (ttm) | -0.04 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.3 |
| Volume | 142,692 |
| Avg. Volume (20D) | 896,159 |
| Open | 0.30 |
| Previous Close | 0.30 |
| Day's Range | 0.28 - 0.31 |
| 52-Week Range | 0.25 - 6.22 |
| Beta | undefined |
About OGEN
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 25, 2004
Employees 5
Stock Exchange AMEX
Ticker Symbol OGEN
Website https://www.oragenics.com
3 months ago ·
Source
+6.39%
Oragenics shares are trading higher after the comp...
Unlock content with
Pro Subscription
4 months ago ·
Source
-46.2%
Oragenics shares are trading lower after the company announced $4.45 million public offering of 8,106,584 shares at $0.55 per share.
10 months ago · businesswire.com
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat ConcussionSARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced ...